“Our Vintechl family of products had robust growth in the quarter, though we are seeing the impact of competition with a new market entrant, and we anticipate this will continue through the year.”

In context

“mir Malik, our Chief US Commercial Officer, and Alexandre de Germay, our Chief International Commercial Officer, we refined our commercial model to bring heightened focus, helping us strategically prioritize our most impactful products and resources. It is working well. In the US, our team demonstrated focus, the strength of our key products, and continuous improvement in execution. Internationally, we are back to personal growth in the first quarter across all parts of the division. This was the result of prioritization and disciplined focus on key growth drivers to maximize return and accelerate new product penetration there. Our performance was strong in both the US and international markets across several key products, including the Wintercare family, Nortech, Tatserv, and Blurbbrand. Our Vintechl family of products had robust growth in the quarter, though we are seeing the impact of competition with a new market entrant, and we anticipate this will continue through the year. We will work towards maintaining our market-leading position that has come from six years of establishing credibility and expertise with the cardiology community. Our team remains committed to addressing high unmet patient need by helping to improve diagnosis and ensuring appropriate patients with ATTR cardiomyopathy receive treatment. Demand continues to strengthen for Northrop America, with revenue growing 40% in the quarter. Our commercial teams effectively engaged with healthcare professionals, and we were pleased with the strong outperformance of our newly launched consumer campaigns. We are pleased with the continued strength also for our oncology portfolio. Tatsit, for example, grew 25% of revenue driven by increased market share in first-line metastatic urothelial cancer. Well, Br”